Investigational drug · Phase 2
CTH120
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Fragile X Syndrome (FXS), Fragile X Syndrome.
Phase 2Last checked: Nov 20, 2026Latest source record: Jul 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "CTH120"
First trial start
2026
May 21, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "CTH120", any sponsor or status.
Conditions studied
As listed on its trial records.
- Fragile X Syndrome (FXS)
- Fragile X Syndrome
Approved drugs for the same conditions: Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "CTH120" as an intervention, largest first.
- CTH120 First-in-Human Study: Single and Multiple Ascending Doses and Potential Food InteractionCompleted
Connecta Therapeutics, S.L.Industry
NCT06480968 · 76 participants · Start Jun 23, 2023 · Primary completion Nov 11, 2024
Drug: CTH120 · For: Fragile X Syndrome
Sites: Barcelona, Spain
Connecta Therapeutics, S.L.Industry
NCT07654114 · 30 participants (planned) · Start May 21, 2026 · Primary completion May 2027
Drug: CTH120 · For: Fragile X Syndrome (FXS); Fragile X Syndrome
Sites: Barcelona, Spain; Sabadell, Spain
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Fragile X Syndrome (FXS)
- SPG601CodabakalnerPhase 32 trials
Spinogenix · Fragile X Syndrome (FXS), Autism Spectrum Disorder (ASD), Fragile X Syndrome
- cannabidiol as a clear that can be applied to the skinZYN002, transdermal deliveryPhase 31 trial
Harmony Biosciences Management, Inc. · Fragile X Syndrome, Fragile X Syndrome (FXS)
- S247240Phase 21 trial
Institut de Recherches Internationales Servier (I.R.I.S.) · Fragile X Syndrome (FXS)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.